Drug Profile

Rengalin - Materia Medica

Alternative Names: Rengalin

Latest Information Update: 23 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Materia Medica Holding Research and Production Company
Developer Materia Medica Holdings
Class Antibodies; Antitussives
Mechanism of Action Histamine release modulators; Inflammation mediator modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Cough

Most Recent Events

15 Sep 2025 Materia Medica Holding plans a phase III trial for Cough (In children, In infants) in Russia (PO) in October 2025 (NCT07171099)
17 May 2017 Materia Medica plans a phase IV trial for Cough in Russia (NCT03159091)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com